Michael Gilman, Ph.D. is Founder and Chief Executive Officer of Stromedix, a venture-backed company focused on developing novel therapies for fibrosis and organ failure. Prior to founding Stromedix, Dr. Gilman spent over six years at Biogen Idec, most recently as Executive Vice President, Research. Dr. Gilman spent the previous five years at ARIAD Pharmaceuticals, where he was Executive Vice President and Chief Scientific Officer. From 1986 to 1994, Dr. Gilman was on the scientific staff of Cold Spring Harbor Laboratory in New York, where his research focused on mechanisms of signal transduction and gene regulation. Dr. Gilman holds a Ph.D. in Biochemistry from University of California, Berkeley, and a S.B. in Life Sciences from Massachusetts Institute of Technology.